8 Targeted Protein Degradation conferences in 2023 you won’t want to miss

February 6, 2023 NanoTemper Technologies

bicycle race drawing with vibrant colors that represents the energy in the Targeted Protein Degradation therapeutics space in 2023

2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race is on.

PROTACs and molecular glue degraders are no longer seen as an unproven modality. It’s now the norm for a pharma company to have protein degraders in their drug discovery pipelines, focusing on elusive ‘undruggable’ high-value targets. And biotech start-ups with degrader platforms are securing investments, even with the widespread decline in funding.

Yet the field is still young enough that the founders of early TPD companies are at all the conferences delivering the plenary talks. You’ll hear the latest news directly from company founders, CEOs, CSOs, SVPs, and scientific directors who made the initial discoveries that got the field started.

Choose from these 8 conferences to catch up on recent progress, discover the latest approaches, and be among the first to hear big announcements. Save this quick-reference summary of 2023 TPD conferences.


1. Molecular Glue Drug Development Summit

Jan 24–26, Boston, USA

Be among the first to attend a conference focused exclusively on molecular glue degraders. Join leading chemists, biologists, bioinformaticians, structural scientists, and computational chemists from around the world to accelerate the first wave of molecular glues into the clinic.

What’s on the agenda

  • Novel mechanisms of newly discovered molecular glues
  • Rational design approaches for next-generation glues
  • Library-specific screening and identification assays
  • Tools to discover new targets and assess ternary complex formation


2. Protein Degradation & Targeting Undruggables Congress

Mar 15–16, Boston, USA

This two-day congress connects leaders from biopharma and academic institutions to share insights and novel approaches to target the undruggable and expand the scope of therapeutically reachable targets.

What’s on the agenda

  • Advances in rational discovery & design of molecular glues and their role in expanding the druggable proteome
  • New approaches with antibody-based degraders, and proximity-induced stabilization
  • Computational approaches to predict productive PROTAC ternary complexes, and mapping degradability of targets


3. Targeted Protein Degradation (TPD) Europe Summit

March 28–30, London, UK

Now in its third year, this event gathers key European biopharma leaders and global TPD experts to share updates and dive into the biggest challenges in early discovery and preclinical stages. This is a more technical- and mechanistic-centered forum.

What’s on the agenda

  • Next-generation approaches and novel degradation mechanisms
  • Computational modeling of TPD to improve structural predictions
  • Use of enhanced assay selection and development for optimization of degrader design
  • How mechanistic cascades inform degrader discovery and design


4. Drug Discovery Chemistry: Protein Degraders & Molecular Glues Track

Apr 10–13, San Diego, USA

Drug Discovery Chemistry has been connecting technical experts, project directors, and innovators from all areas of small molecule therapeutics for 18 years. With more than 10 concurrent tracks, you can catch up on TPD, and expand your understanding of adjacent topics.

What’s on the agenda

  • New strategies to target extracellular proteins, transcription factors, and other elusive targets
  • How approaches to improve drug-like properties of PROTACs have fared in the effort to overcome ADME challenges
  • How structural and biophysical characterization of ternary complexes informs understanding of degradation efficiencies and recruitment mechanisms


5. Ligase Targeting Drug Development Summit

Apr 11–13, Boston, USA

As its name implies, the focus of this conference is on using E3 ligases in TPD. Catch up on recent findings, and learn about novel approaches with newly discovered and underexploited E3 ligases.

What’s on the agenda

  • Unexploited ubiquitin ligases – structure, function, and therapeutic potential
  • Computational approaches for early ligase and ligand discovery
  • How ligases are being used to inhibit — rather than degrade targets — and the associated advantages and drawbacks


6. Discovery on Target — PROTACs and Molecular Glues Track

Sept 25–29, Boston, USA

Now in its 23rd year, Discovery on Target brings together drug discovery professionals building therapeutics ranging from biologics to small molecules.

Learn about progress on current and emerging drug targets and technologies, and target validation strategies for the discovery and development of new therapeutic agents.

With multiple concurrent sessions over five days, you can catch up on advances in TPD, and broaden your knowledge about other approaches and therapeutics.

What’s on the agenda

  • Emerging modalities breakthroughs for hard-to-drug targets
  • Advances in AI approaches
  • New tools that accelerate the discovery and characterization of degraders


7. Targeted Protein Degradation (TPD) Summit

Date and location TBA

The 2022 summit, last held in Boston Oct 22–25, 2022, saw a record number of first disclosures of data delivered by industry leaders. You can count on even more findings to be revealed in 2023.

Join experts from large pharma, innovative biotech, and renowned academics to discuss the full breadth of protein degrader drug development — from discovery to clinical development and manufacturing.

What’s on the agenda

  • Industry leaders’ first disclosures of pre-clinical and clinical data
  • Next-generation strategies for difficult-to-drug targets
  • Pre-conference workshops and boot camps for those new to TPD


8. TPD Assay Development & Screening Summit

Date and location TBA

PROTACs are now an accepted therapeutic modality, and they’re here to stay. But they bring their own challenges to scale-up and screening campaigns. Expect lots of progress in this relatively new area. Check the conference website for details of this follow-up to a highly successful inaugural summit that was held in Boston Dec 6–8, 2022.

Join a small but mighty group of early discovery scientists with expertise in assay development, and screening strategies. Learn how they identify new targets, discover novel ligands, and move them from early discovery to drug candidate.

What’s on the agenda

  • Experts will present case studies and share actionable insights on the unique challenges screening degrader candidates
  • New technologies and approaches to overcome challenges with scale-up and high-throughput screening
  • Approaches to optimize in vitro assays to better predict in vivo function


Amplify your experience with a little extra effort

After registering for a conference, it’s time to move on to planning. It doesn’t take a lot of time to select the sessions you’ll be attending, and to set up meetings. And it sets you up to get the most out of your experience.

For more conference preparation tips: How to get the most out of scientific conferences


More resources on PROTACs:

If you’re facing challenges characterizing your PROTAC leads: Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

If you’re struggling with affinity screening campaigns: Put your challenging affinity screening campaigns back on track

Previous Article
How early discovery and development teams use DLS to de⁠-⁠risk downstream biologics development
How early discovery and development teams use DLS to de⁠-⁠risk downstream biologics development

As a discovery or early development scientist, you’re tasked with identifying the most promising biologics ...

Up next
8 biologics conferences you won’t want to miss in 2023
8 biologics conferences you won’t want to miss in 2023

When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeuti...